132 related articles for article (PubMed ID: 36058112)
21. Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1.
Vernole P; Muzi A; Volpi A; Terrinoni A; Dorio AS; Tentori L; Shah GM; Graziani G
Mutat Res; 2011 Jul; 712(1-2):40-8. PubMed ID: 21570414
[TBL] [Abstract][Full Text] [Related]
22. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
Pratz KW; Koh BD; Patel AG; Flatten KS; Poh W; Herman JG; Dilley R; Harrell MI; Smith BD; Karp JE; Swisher EM; McDevitt MA; Kaufmann SH
Clin Cancer Res; 2016 Aug; 22(15):3894-902. PubMed ID: 26979391
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.
Hegan DC; Lu Y; Stachelek GC; Crosby ME; Bindra RS; Glazer PM
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2201-6. PubMed ID: 20133863
[TBL] [Abstract][Full Text] [Related]
24. Electrophilic fatty acids impair RAD51 function and potentiate the effects of DNA-damaging agents on growth of triple-negative breast cells.
Asan A; Skoko JJ; Woodcock CC; Wingert BM; Woodcock SR; Normolle D; Huang Y; Stark JM; Camacho CJ; Freeman BA; Neumann CA
J Biol Chem; 2019 Jan; 294(2):397-404. PubMed ID: 30478172
[TBL] [Abstract][Full Text] [Related]
25. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
26. Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining.
Kobayashi S; Kasaishi Y; Nakada S; Takagi T; Era S; Motegi A; Chiu RK; Takeda S; Hirota K
Oncogene; 2015 Aug; 34(33):4403-11. PubMed ID: 25417706
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.
Vernole P; Muzi A; Volpi A; Dorio AS; Terrinoni A; Shah GM; Graziani G
Mutat Res; 2009 May; 664(1-2):39-47. PubMed ID: 19428379
[TBL] [Abstract][Full Text] [Related]
28. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
29. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
Clements KE; Schleicher EM; Thakar T; Hale A; Dhoonmoon A; Tolman NJ; Sharma A; Liang X; Imamura Kawasawa Y; Nicolae CM; Wang HG; De S; Moldovan GL
Nat Commun; 2020 Nov; 11(1):6118. PubMed ID: 33257658
[TBL] [Abstract][Full Text] [Related]
30. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Trenner A; Godau J; Sartori AA
Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
32. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
33. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
[TBL] [Abstract][Full Text] [Related]
34. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Adimoolam S; Sirisawad M; Chen J; Thiemann P; Ford JM; Buggy JJ
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19482-7. PubMed ID: 18042714
[TBL] [Abstract][Full Text] [Related]
35. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.
Zhao L; Si CS; Yu Y; Lu JW; Zhuang Y
Cancer Sci; 2019 Nov; 110(11):3543-3552. PubMed ID: 31541611
[TBL] [Abstract][Full Text] [Related]
36. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
Pfäffle HN; Wang M; Gheorghiu L; Ferraiolo N; Greninger P; Borgmann K; Settleman J; Benes CH; Sequist LV; Zou L; Willers H
Cancer Res; 2013 Oct; 73(20):6254-63. PubMed ID: 23966292
[TBL] [Abstract][Full Text] [Related]
37. TOPORS-mediated RAD51 SUMOylation facilitates homologous recombination repair.
Hariharasudhan G; Jeong SY; Kim MJ; Jung SM; Seo G; Moon JR; Lee S; Chang IY; Kee Y; You HJ; Lee JH
Nucleic Acids Res; 2022 Feb; 50(3):1501-1516. PubMed ID: 35061896
[TBL] [Abstract][Full Text] [Related]
38. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
39. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
40. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Naipal KA; Verkaik NS; Ameziane N; van Deurzen CH; Ter Brugge P; Meijers M; Sieuwerts AM; Martens JW; O'Connor MJ; Vrieling H; Hoeijmakers JH; Jonkers J; Kanaar R; de Winter JP; Vreeswijk MP; Jager A; van Gent DC
Clin Cancer Res; 2014 Sep; 20(18):4816-26. PubMed ID: 24963051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
